We are focusing on saving people’s eyesight from the leading causes of vision loss through pioneering therapies and cutting- edge research. Vision loss affects 253 million people worldwide, presenting a major global health problem and diseases of the retina are among the main causes of visual impairment globally.
We have the broadest late stage retina pipeline including treatments for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR) and retinal vein occlusion (RVO). Our robust early stage pipeline also includes gene therapies and treatments for geographic atrophy (GA).
Our experienced team of ophthalmologists, scientists and researchers are working to develop innovative solutions that have the potential to redefine standards of care for retinal diseases.
Forsight Vision4 – Acquisition to acquire Port Delivery system for long-acting ocular delivery
Ionis – collarabotion to develop IONIS-FB-LRx targeting Factor B (FB) for a broad range of diseases including Geographic Atrophy (GA) and dry age-related macular degeneration (AMD)
4D Molecular Therapeutics – collaboration and license agreement to discover and develop optimized next-generation AAV vectors for indications with high unmet medical need.
Tom Zioncheck, Head of Neuroscience, Ophthalmology and Rare Diseases, Pharma Partnering
J.C. Lopez, Search & Evaluation Lead Neuroscience, Ophthalmology & Rare Diseases, Pharma Partnering